Previous Close | 30.78 |
Open | 30.79 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 30.79 - 30.80 |
52 Week Range | 28.00 - 67.80 |
Volume | |
Avg. Volume | 39,667 |
Market Cap | 30.249B |
Beta (5Y Monthly) | 0.97 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.24 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.12 (0.39%) |
Ex-Dividend Date | Apr 29, 2024 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for BAYZF
(Bloomberg) -- Shares of Boundless Bio Inc., a cancer therapeutics maker that counts Bayer AG among its largest investors, fell nearly 11% after raising $100 million in a US initial public offering.Most Read from BloombergBankman-Fried Is Sentenced to 25 Years in Prison Over FTX CollapseTesla’s $25,000 Car Means Tossing Out the 100-Year-Old Assembly LineDubai Is Losing Its Allure for Wealthy RussiansLondon Insurers Face Baltimore Bridge Payouts Worth BillionsUBS Banker’s Frustration Exposes Crac
(Bloomberg) -- Boundless Bio Inc., a cancer therapeutics maker that counts Bayer AG among its largest investors, raised $100 million in a US initial public offering after pricing shares at the midpoint of a marketed range.Most Read from BloombergLondon Insurers Face Baltimore Bridge Payouts Worth BillionsBiden Gains Ground Against Trump in Six Key States, Poll ShowsJapan Amps Up Intervention Threat as Yen Hits Lowest Since 1990Trump’s Net Worth Hits $6.5 Billion, Making Him One of World’s 500 Ri
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.